Thanks BDAZ.  

One item that I never fully understood is why RVX put plaque regression as a primary end point in the ASSURE trials.  

While the idea of a roto rooter for your arteries sounds like a great idea, we know that plaque regression by itself does not mean much.  I assume that RVX took the idea of reverse cholesterol transport to its logical conclusion...still, why not specify LDL reductions &/or HDL increases as primary end points?  Given the medical profession's near obsession with LDL, would that not have been an easier idea to sell?